NOT ALL BRCA2 GENE CHANGES ARE EQUAL: WHAT NEW BREAST CANCER RESEARCH MEANS FOR YOU

For many women, hearing the word BRCA2 after a genetic test can feel like the ground has shifted beneath their feet.
Now new research suggests that not every BRCA2 gene change carries the same level of breast cancer risk, and that could change the conversations women have with their doctors.
The study, led by Mayo Clinic in the United States with genetic testing company Ambry Genetics, was published in Nature Communications and reported by News-Medical on November 17.
A quick refresher on BRCA2
We all carry the BRCA1 and BRCA2 genes, which normally help repair damaged DNA and keep cells from growing out of control.
When one of these genes carries a harmful change, known as a variant, that repair system does not work as well, and the risk of certain cancers rises.
The best-known harmful BRCA2 variants are linked to an estimated 50 to 70 per cent lifetime risk of breast cancer.
Those are the figures many women hear about, and they often lead to tough decisions about extra screening or risk-reducing surgery.
What the new BRCA2 study found
The Mayo Clinic team looked closely at 70 BRCA2 variants that only partly disrupt how the gene works.
Scientists call these "hypomorphic" variants, which simply means the gene still functions, just not at full strength.
The researchers tested how each variant affected BRCA2 activity in the lab, then compared the results with genetic testing data from a large number of people who had been checked for hereditary cancer.
They found that people carrying these partly working variants had an estimated lifetime breast cancer risk of 20 to 25 per cent.
That is still higher than average, but it is a long way below the 50 to 70 per cent linked to the more familiar variants.
Because of this, the team has classed them as "reduced penetrance" pathogenic variants, a label for gene changes that raise risk, but by less.
Breast cancer researcher Fergus Couch summed it up neatly: "This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk."
Why this matters for women
Until now, some of these variants may have been hard to interpret, leaving women and their doctors unsure how worried to be.
A clearer risk estimate could help women make choices that suit their own situation.
For example, the researchers say carriers may still qualify for, and benefit from, regular mammograms and breast MRI scans.
At the same time, a more precise figure could help inform decisions about major steps such as risk-reducing surgery.
There is also a possible treatment angle.
The study notes that some breast cancers linked to these variants may respond to a group of medicines called PARP inhibitors, and testing the tumour itself could help show whether they are a good fit.
The team says it is continuing to hunt for similar partly working variants in both BRCA1 and BRCA2.
What to do if BRCA2 runs in your family
If you have already had a genetic test and were told you carry a BRCA2 variant, it is worth asking your doctor or genetic counsellor exactly which type you have.
Classifications can be updated as new research like this emerges, so it may be worth checking whether your result has been reviewed recently.
If breast or ovarian cancer runs in your family but you have not been tested, speak to your GP, who can talk you through your family history and whether a referral to a family cancer clinic makes sense.
In Australia, women aged 50 to 74 are invited for a free mammogram every two years through BreastScreen Australia, and women in their forties can also book.
Whatever your family history, get to know how your breasts normally look and feel, and see your GP promptly about any changes, such as a new lump, skin dimpling or nipple changes.
You can read the full research paper in Nature Communications.
The message from this study is a reassuring one: a gene result is not one size fits all, and better information means better choices.









